Shamburg News · 8-K filed Nov 12, 2026, 4:06 PM EST
Evommune Reports Q3 2026 Net Loss of $30.9 Million, Provides Pipeline Update
EVMN · Evommune, Inc.
- Earnings
- Reg FD disclosure
- Financing
- Materiality: high
Evommune, Inc. reported financial results for the third quarter ended September 30, 2026, with no revenue compared with $10.0 million a year earlier, and a net loss of $30.9 million, or $(0.85) per share. Research and development expenses were $24.6 million and general and administrative expenses were $8.8 million for the quarter. The company also furnished an updated corporate presentation, and its press release described the in-licensing of EVO570 and a concurrent $30 million private placement.
Source: SEC EDGAR, Form 8-K, Items 2.02, 7.01, accession 0001193125-26-458329.
Written from the filing by Shamburg Markets. Figures are as reported by the company.